We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Uses Infrared Light to Detect Brain Cancer

By LabMedica International staff writers
Posted on 23 Oct 2023

Every year, more than 86,000 new brain cancer cases are identified globally, and these tend to be more costly to treat initially than other types of cancer. More...

The average life span is cut short by about 20 years due to brain tumors. An early diagnosis greatly improves the chances of successful treatment and a better quality of life. However, in primary healthcare settings, diagnosing brain cancer is extremely challenging. Most patients exhibit symptoms that are vague and usually not immediately life-threatening, making it tough to determine who needs further, expensive testing like brain scans. Now, an innovative liquid biopsy using spectroscopy offers a quick, affordable, and accurate method for doctors to test for brain cancer, cutting down on delays for additional tests and treatments.

Dxcover’s (Glasgow, UK) brain cancer blood test utilizes infrared light on blood samples to assess whether a patient is likely to have cancer. This approach is grounded in research showing that the interplay between the light and molecules in the blood can generate a biological signal. This signal is then analyzed using machine learning to ascertain if the patient has cancer. In the test, a tiny amount of blood serum is dried onto a specialized Dxcover Slide and then examined using infrared light. All critical data, including how the body is responding to potential illness, is recorded. An AI algorithm quickly processes this information, even offering insight into the type and intensity of the tumor, helping healthcare providers to prioritize treatment plans more effectively.

In a 2021 study, the test successfully identified glioblastoma, a particularly aggressive form of brain tumor, with 91% sensitivity and 80% specificity. Overall, the test had an 81% sensitivity rate for all kinds of brain tumors. Dxcover is continually fine-tuning the test's accuracy for various applications. The highly sensitive nature of the test enables doctors to efficiently triage patients and rule out cancer as a cause for their symptoms. Dxcover plans to introduce its blood test in Europe to aid in the assessment of patients showing symptoms of cancer. The company expects to finalize clinical trials and secure a CE Mark for the test’s commercial release in the European Union by 2025. Meanwhile, in the United States, the test's high specificity could prove instrumental in detecting brain cancer at an earlier stage, according to the company.

Related Links:
Dxcover


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
Image: Pancreatic cancer diagnosis (Photo courtesy of World Journal of Gastroenterology)

AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis

Pancreatic cancer poses a major global health threat due to its high mortality rate, with 467,409 deaths and 510,992 new cases reported worldwide in 2022. Often referred to as the "king" of all cancers,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.